Supplementary Figure S3 from Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN–Associated and Sporadic NF2-Deficient Meningiomas
Abstract
Figure S3. The AG-NF2-Men cell line exhibited a slow doubling time, consistent with the growth characteristics of a benign tumor.
Fields of Study & Subjects
Meningioma and schwannoma management
Neurofibromatosis and Schwannoma Cases
PI3K/AKT/mTOR signaling in cancer
Publication details
- Publication date
- 27 January 2026